Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Test Detects Rheumatoid Arthritis in At-Risk Individuals Before Symptoms

By LabMedica International staff writers
Posted on 06 Oct 2025

Rheumatoid arthritis (RA) is a debilitating autoimmune disorder that causes chronic joint inflammation, pain, and disability. More...

For decades, doctors have diagnosed the disease only after symptoms appear, by which time irreversible damage has often occurred. Millions of people endure years of misdiagnosis and progressive pain before treatment begins. Now, clinical tests could detect new early-warning signs (biomarkers and immune signatures) to identify who among at-risk individuals is most likely to develop RA.

In a seven-year study, researchers at the Allen Institute (Seattle, WA, USA) and the University of Colorado Anschutz (Aurora, CO, USA), along with collaborators, analyzed individuals carrying anticitrullinated protein antibodies (ACPAs) known biomarkers for RA risk — the team mapped how the immune system changes long before joint symptoms appear. The study provides the most detailed timeline yet of how RA develops from invisible immune dysfunction to full-blown disease.

The researchers tracked hundreds of at-risk participants over several years, studying the behavior of immune cells and gene activity across multiple tissues. They found widespread inflammation throughout the body, even before localized joint swelling began. Immune cells, such as B cells and T helper cells, shifted toward a pro-inflammatory state, while “naive” T cells exhibited early epigenetic reprogramming. The study also detected monocytes in the bloodstream resembling macrophages from inflamed joints, suggesting that the body was already preparing for joint-specific attacks.

These findings, published in Science Translational Medicine, provide powerful early-warning indicators that could allow clinicians to identify who among at-risk individuals is most likely to develop RA. Detecting these immune signatures in advance could enable doctors to monitor high-risk patients more closely and intervene before tissue damage occurs. By catching the disease at its earliest, invisible stage, the research points toward a major shift from reactive treatment to proactive prevention of autoimmune diseases.

The study’s insights into immune cell behavior could also help refine existing therapies or guide the development of new biologics targeting inflammation earlier in the disease process. Future research will aim to translate these biomarkers into clinical tests capable of predicting disease onset and identifying patients who would benefit most from early intervention.

“Overall, we hope this study raises awareness that rheumatoid arthritis begins much earlier than previously thought and that it enables researchers to make data-driven decisions on strategies to disrupt disease development,” said Mark Gillespie, Ph.D., co-senior author of the study.

Related Links:
Allen Institute
University of Colorado Anschutz


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.